A novel oncolytic vaccinia virus (NOV) was demonstrated with the dual advantages of cancer selectivity and normal vessel reconstructive activity by replacing the viral thymidine kinase (vTk) and vaccinia growth factor (VGF) genes with genes encoding TNF-related apoptosis-inducing ligand (TRAIL) and angiopoietin 1 (Ang1). The gene discussed is TNFSF10; the disease is cancer.